Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,159.00-1.06%ETH$2,457.98+0.19%GOLD$4,362.00-1.03%OIL$104.04+1.52%
Smart Investors Daily
EL

NASDAQ · ELTX

Elicio Therapeutics, Inc.

Healthcare · Biotechnology

$2.18

Down-$0.07 (-3.21%)

Updated Sep 10, 2026, 9:19 PM

SID Score

2.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
144.37M
P/E ratio
-3.04
Dividend yield
0.00%
52-week range
$2.17 – $16.00
Volume
459.08K
Avg. volume
97.45K

Price performance

ELTX price history

1M range · 20 trading sessions · Daily adjusted prices

ELTX closed at $2.18 after 20 trading sessions, down 28.76% for the selected period.

Last close
$2.18
Period change
-28.76%
Period low
$2.18
Period high
$3.15
Daily close
View OHLC price history
ELTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 9, 2026$2.37$2.375$2.17$2.18459.08K
Sep 8, 2026$2.42$2.46$2.34$2.35324.72K
Sep 4, 2026$2.50$2.50$2.36$2.41487.92K
Sep 3, 2026$2.55$2.56$2.465$2.50272.71K
Sep 2, 2026$2.57$2.61$2.48$2.55397.65K
Sep 1, 2026$2.70$2.71$2.55$2.56334.84K
Aug 31, 2026$2.84$2.8699$2.70$2.70412.19K
Aug 28, 2026$3.00$3.00$2.84$2.84421.56K
Aug 27, 2026$3.00$3.05$2.97$3.00131.24K
Aug 26, 2026$3.00$3.07$2.96$2.98182.66K
Aug 25, 2026$3.00$3.095$2.9804$3.01223.61K
Aug 24, 2026$3.06$3.06$2.94$2.98311.99K
Aug 21, 2026$3.11$3.11$3.03$3.04279.37K
Aug 20, 2026$3.11$3.135$3.02$3.075207.77K
Aug 19, 2026$3.34$3.36$3.04$3.13502.61K
Aug 18, 2026$3.03$3.12$2.98$3.11389.1K
Aug 17, 2026$3.05$3.085$3.00$3.02253.44K
Aug 14, 2026$3.16$3.205$3.05$3.09155.52K
Aug 13, 2026$3.10$3.185$3.0514$3.15139.57K
Aug 12, 2026$3.01$3.08$3.01$3.06140.62K

Latest ELTX news

The latest Smart Investors Daily articles mentioning ELTX.

Stock researchCompany · Overview

ELTX research

Overview

Company profile and research snapshot.

Company profile

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
ELTX recent ratings
DateFirmRatingTarget
Aug 18, 2026HC Wainwright & Co.Buy—
Jun 16, 2026Jones TradingHold—
Jun 15, 2026HC Wainwright & Co.Buy—
Jun 10, 2026B. Riley SecuritiesBuy—
May 28, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York. H.C

Yahoo · Aug 13, 2026

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026 While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups, including the R0 resected population, to further refine its Phase 3 development strategy for ELI-002

Benzinga · Aug 13, 2026

Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By